Market Research Logo

Fibrosis - Pipeline Review, H2 2015

Fibrosis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Fibrosis - Pipeline Review, H2 2015’, provides an overview of the Fibrosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Fibrosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Fibrosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Fibrosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Fibrosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Fibrosis Overview
Therapeutics Development
Pipeline Products for Fibrosis - Overview
Pipeline Products for Fibrosis - Comparative Analysis
Fibrosis - Therapeutics under Development by Companies
Fibrosis - Therapeutics under Investigation by Universities/Institutes
Fibrosis - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Fibrosis - Products under Development by Companies
Fibrosis - Products under Investigation by Universities/Institutes
Fibrosis - Companies Involved in Therapeutics Development
Abeome Corporation
Acceleron Pharma, Inc.
Complexa, Inc.
Digna Biotech, S.L.
F. Hoffmann-La Roche Ltd.
FibroGen, Inc.
GlycoMimetics, Inc.
HanAll Biopharma Co., Ltd.
Isarna Therapeutics GmbH
Lycera Corp.
miRagen Therapeutics, Inc.
Neumedicines Inc.
Ribomic Inc.
RuiYi Inc.
Scholar Rock, Inc.
Siena Biotech S.p.A.
Silence Therapeutics Plc
SK Chemicals Co., Ltd.
UCB S.A.
XOMA Corporation
Fibrosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ACE-2531 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antibodies for Fibrosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antibody to Inhibit Transglutaminase 2 for Fibrosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
disitertide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug to Activate Insulin Like Growth Factor for Fibrosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
G-XXX - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HL-156FIB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IB-DMD - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ISTH-1047 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MGN-4220 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies to Inhibit IL-25 for Asthma, Fibrosis and Atopic Dermatitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies to Inhibit TGF-beta 1 for Fibrosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NCE-401 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NMIL-121 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NPH-09 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
P-006 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PRI-724 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RBM-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RBM-007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RG-6069 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RNAi Oligonucleotide for Liver Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RYI-028 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit Galectin-3 for Fibrosis, Cancer and Cardiovascular Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit LOXL2 for Fibrosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit MicroRNA for Vascular Fibrosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit Rho Kinase for Fibrosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit Tankyrase/Wnt for Musculoskeletal, CNS and Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Inflammatory Diseases and Fibrosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Antagonize S1P3 for Inflammation, Neurodegenerative Diseases and Fibrosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Procollagen C-Proteinase for Fibrosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit SMURF2 for Fibrosis, Oncology and IBD - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit SphK1 for Oncology, Autoimmune Disorders, Fibrosis and Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Trophokine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XOMA-089 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fibrosis - Recent Pipeline Updates
Fibrosis - Dormant Projects
Fibrosis - Dormant Projects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Fibrosis, H2 2015
Number of Products under Development for Fibrosis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015
Fibrosis - Pipeline by Abeome Corporation, H2 2015
Fibrosis - Pipeline by Acceleron Pharma, Inc., H2 2015
Fibrosis - Pipeline by Complexa, Inc., H2 2015
Fibrosis - Pipeline by Digna Biotech, S.L., H2 2015
Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Fibrosis - Pipeline by FibroGen, Inc., H2 2015
Fibrosis - Pipeline by GlycoMimetics, Inc., H2 2015
Fibrosis - Pipeline by HanAll Biopharma Co., Ltd., H2 2015
Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2015
Fibrosis - Pipeline by Lycera Corp., H2 2015
Fibrosis - Pipeline by miRagen Therapeutics, Inc., H2 2015
Fibrosis - Pipeline by Neumedicines Inc., H2 2015
Fibrosis - Pipeline by Ribomic Inc., H2 2015
Fibrosis - Pipeline by RuiYi Inc., H2 2015
Fibrosis - Pipeline by Scholar Rock, Inc., H2 2015
Fibrosis - Pipeline by Siena Biotech S.p.A., H2 2015
Fibrosis - Pipeline by Silence Therapeutics Plc, H2 2015
Fibrosis - Pipeline by SK Chemicals Co., Ltd., H2 2015
Fibrosis - Pipeline by UCB S.A., H2 2015
Fibrosis - Pipeline by XOMA Corporation, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Fibrosis Therapeutics - Recent Pipeline Updates, H2 2015
Fibrosis - Dormant Projects, H2 2015
List of Figures
Number of Products under Development for Fibrosis, H2 2015
Number of Products under Development for Fibrosis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report